semaglutide long acting (SYH9017) / CSPC Pharma - LARVOL DELTA

CSPC Pharmaceutical Group Limited…is pleased to announce that the Semaglutide Long-acting Injection (SYH9017) (the 'Product'), a GLP-1 receptor agonist developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. (HKEXnews) - "The indication for this clinical trial approval is weight management in adults who are overweight or obese, along with a reduced-calorie diet and increased physical activity."

IND • Obesity

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity